Antibody drug conjugates make strides in ovarian cancer with recent FDA approval
University of California, Los Angeles (UCLA), Health SciencesThe UCLA team played a pivotal role in a clinical trial that led to the FDA granting accelerated approval of the first antibody drug conjugate (ADC), mirvetuximab soravtansine, for the treatment of platinum-resistant ovarian cancer.